1 / 5

21 July, 2011 Oral poster discussion session, 6th IAS Conference, Roma

Causes of death and risk factors of mortality in HIV-infected patients treated for tuberculosis enrolled in the CAMELIA trial (ANRS 1295/12160 – CIPRA KH001/10425).

ataret
Download Presentation

21 July, 2011 Oral poster discussion session, 6th IAS Conference, Roma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Causes of death and risk factors of mortality in HIV-infected patients treated for tuberculosis enrolled in the CAMELIA trial (ANRS 1295/12160 – CIPRA KH001/10425) O. Marcy, D. Laureillard, S. Chan, Y. Madec, C. Mayaud, L. Borand, N. Prak, C. Kim, K.K. Lak, C. Hak, B. Dim, T. Sok, A.E. Goldfeld and F.X. Blanc 21 July, 2011 Oral poster discussion session, 6th IAS Conference, Roma

  2. Study design • HIV+ patients with AFB+ tuberculosis (TB) and CD4 ≤ 200/mm3 • TB regimen: 2RHEZ/4RH • Randomized to start ART (D4T/3TC/EFV) • Early: 2 weeks after TB treatment onset • Late: 8 weeks after TB treatment onset • Primary endpoint: survival • Causes of death were secondarily assessed ANRS 1295/12160 – CIPRA KH001/10425 study

  3. Mortality • Median follow-up duration: 25 months • 149 / 661 (22%) enrolled patients died • Place of death: • 63 (42%) deaths occurred at home • 86 (58%) occurred in hospital ANRS 1295/12160 – CIPRA KH001/10425 study

  4. Causes of death ANRS 1295/12160 – CIPRA KH001/10425 study

  5. Risk factors of mortality

More Related